Sonia T. Oskouei, PharmD, vice president of innovation and solution development at Premier Inc, discusses what she will be watching closely in the biosimilars space in early 2020.
Transcript
In early 2020, I think what I'm going to be very interested in seeing is how the market responds to having multiple biosimilars in certain their therapeutic areas. We're already seeing it with the pegfilgrastims now. There's more and more becoming available, and there was just one approved yesterday.* So to understand how health systems are going to really make the decision between multiple options for biosimilars is what I'm going to be really looking out for, and whether or not it's really going to come down just to the price, if there's going be any differentiator as part of it I think will be interesting to see.
*As of the date of filming.
Panelists Call for Consistent Education, Support to Improve Patient Comfort With Biosimilars
May 15th 2024At the Festival of Biologics USA, panelists stressed the need for patient-centered communication and education to boost comfort with biosimilars, emphasizing consistent support from health care providers despite restrictive payer policies.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.